NEW YORK (GenomeWeb News) – GeneNews today said that it has executed a formal marketing partnership with GeneDiagnostics to sell its ColonSentry test in China.
The agreement follows a term sheet agreement signed between the partners last month. Financial terms of the agreement have not been disclosed.
The agreement provides GeneDiagnostics with non-exclusive rights to market and sell the ColonSentry test in Shanghai and in the provinces of Zhejiang and Jiangsu. GeneDiagnostics expects to begin selling the test in those areas in the fourth quarter of this year.
ColonSentry is Toronto-based GeneNews' first product and has been launched in Canada, with a commercial introduction expected in the US later this year. It is a blood-based test that is used to pre-screen and assess an individual's current risk for colorectal cancer.